Carla Casulo

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. doi request reprint Treating Burkitt Lymphoma in Adults
    Carla Casulo
    Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA
    Curr Hematol Malig Rep 10:266-71. 2015
  2. pmc A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics
    Carla Casulo
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY, USA Electronic address
    Clin Immunol 154:37-46. 2014
  3. doi request reprint Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma
    Carla Casulo
    Department of Medicine, University of Rochester, Rochester, NY, USA
    Leuk Res 37:1178-83. 2013
  4. pmc 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma
    Carla Casulo
    Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 54:2163-7. 2013

Detail Information

Publications4

  1. doi request reprint Treating Burkitt Lymphoma in Adults
    Carla Casulo
    Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA
    Curr Hematol Malig Rep 10:266-71. 2015
    ..Most Burkitt lymphoma patients are cured with intensive treatment; however, prognosis is poor in elderly patients and those with relapsed disease. ..
  2. pmc A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics
    Carla Casulo
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY, USA Electronic address
    Clin Immunol 154:37-46. 2014
    ....
  3. doi request reprint Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma
    Carla Casulo
    Department of Medicine, University of Rochester, Rochester, NY, USA
    Leuk Res 37:1178-83. 2013
    ..However, the impact of TAM in relapsed and refractory disease is unknown...
  4. pmc 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma
    Carla Casulo
    Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 54:2163-7. 2013
    ..Interim FDG-PET may predict for PFS. FDG-PET should be integrated into prospective trials to confirm these findings...